1. Home
  2. PRT vs ALLR Comparison

PRT vs ALLR Comparison

Compare PRT & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PermRock Royalty Trust Trust Units

PRT

PermRock Royalty Trust Trust Units

HOLD

Current Price

$2.07

Market Cap

25.3M

Sector

Energy

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.61

Market Cap

26.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRT
ALLR
Founded
2017
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.3M
26.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PRT
ALLR
Price
$2.07
$1.61
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.75
AVG Volume (30 Days)
74.2K
223.2K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
13.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$320,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.82
$0.77
52 Week High
$4.28
$2.35

Technical Indicators

Market Signals
Indicator
PRT
ALLR
Relative Strength Index (RSI) 38.04 52.06
Support Level $1.82 $1.53
Resistance Level $3.57 $1.80
Average True Range (ATR) 0.13 0.15
MACD 0.03 -0.02
Stochastic Oscillator 66.67 40.52

Price Performance

Historical Comparison
PRT
ALLR

About PRT PermRock Royalty Trust Trust Units

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Share on Social Networks: